FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall
Executive Summary
Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.
You may also be interested in...
Rise And Fall: PDUFA Fees Go Up But Some GDUFA Levies Come Down In FY 2015
NDA/BLAs with clinical data will cost 7.7% more starting Oct. 1, bringing the application fee to $2.34 million.
GDUFA’s Perfect Storm: Approvals Drop, Submissions Jump
FDA increases “complete response” and refuse-to-receive actions in the first half of FY 2014 compared to the previous year, efforts the agency says will move pending applications closer to approval.
GDUFA: Fee Avoidance Affects Rates Again
Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.